{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C&page=33", "query": { "condition": "Cancer,", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 50439, "total_pages": 5044, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C&page=34&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C&page=32&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T03:31:54.877Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00776802", "title": "GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "GCS-100", "type": "DRUG" }, { "name": "Etoposide; Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "La Jolla Pharmaceutical Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-07", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2013-06-25", "last_synced_at": "2026-11-15T03:31:54.877Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00776802" }, { "nct_id": "NCT04082520", "title": "Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Grade 1 Meningioma", "Grade 2 Meningioma", "Grade 3 Meningioma", "Recurrent Meningioma", "Unresectable Meningioma" ], "interventions": [ { "name": "Gallium Ga 68-DOTATATE", "type": "RADIATION" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2020-04-14", "completion_date": "2032-03-04", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-15T03:31:54.877Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04082520" }, { "nct_id": "NCT07172282", "title": "INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "Nelitolimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2025-11-17", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-11-15T03:31:54.877Z", "location_count": 1, "location_summary": "Lake Success, New York", "locations": [ { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07172282" }, { "nct_id": "NCT01994382", "title": "Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Follicular Lymphoma (FL/Indolent NHL)", "Aggressive NHL (a NHL)", "Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)", "T-cell Lymphoma (PTCL and CTCL)", "B-cell Non Hodgkin Lymphoma (NHL)" ], "interventions": [ { "name": "Cerdulatinib", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2013-08-30", "completion_date": "2020-12-15", "has_results": true, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-11-15T03:31:54.877Z", "location_count": 23, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01994382" }, { "nct_id": "NCT05187182", "title": "CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Cancer", "Esophageal Cancer", "Stomach Cancer", "Esophagus Cancer", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "CA-4948", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "mFOLFOX7", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2023-06-02", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-11-15T03:31:54.877Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05187182" }, { "nct_id": "NCT05627323", "title": "CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme of Brain" ], "interventions": [ { "name": "CHM-1101 CAR-T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Chimeric Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2023-06-06", "completion_date": "2026-05-29", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-11-15T03:31:54.877Z", "location_count": 2, "location_summary": "Duarte, California • Austin, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05627323" }, { "nct_id": "NCT05783323", "title": "Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Differentiated Thyroid Cancer", "Pediatric Cancer", "Cancer", "Cancer, Thyroid" ], "interventions": [ { "name": "Larotrectinib monotherapy", "type": "DRUG" }, { "name": "131I therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "2 Years to 99 Years" }, "enrollment_count": 13, "start_date": "2024-02-14", "completion_date": "2030-10-01", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-11-15T03:31:54.877Z", "location_count": 6, "location_summary": "San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05783323" }, { "nct_id": "NCT00125359", "title": "Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-small-cell Lung" ], "interventions": [ { "name": "erlotinib and bexarotene", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Konstantin Dragnev", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2005-08", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-11-15T03:31:54.877Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • New York, New York", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00125359" }, { "nct_id": "NCT03419559", "title": "Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "LN-145", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-02-28", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-11-15T03:31:54.877Z", "location_count": 8, "location_summary": "La Jolla, California • Los Angeles, California • Louisville, Kentucky + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03419559" }, { "nct_id": "NCT06854159", "title": "Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Odronextamab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2025-08-07", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-11-15T03:31:54.877Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06854159" } ] }